A vertically integrated clay miner where B2B — not cat litter — now drives the incremental dollar

• Retail & Wholesale (62% of FY25 sales). Cat's Pride, Jonny Cat, Ultra Pet crystal litter, and a Fresh Step co-pack for Clorox — 14.6% segment OPM, Walmart at 19% of consolidated sales.
• Business-to-Business (38% of sales, 58% of segment OI). Bleaching clays for renewable diesel and edible oils, Amlan animal health, crop-protection ag carriers — 32.7% segment OPM and the entire growth story.
• 207M tons of owned reserves. Roughly 40+ years of clay supply; the bottleneck is gas-fired kilns and freight, not the dirt.

Structural margin upgrade tripled operating margin and rerated the stock from 8x to 14.5x EBITDA

FY25 revenue $485.6M, net income $54M, FCF $47.6M, net cash $10.6M. Q2-FY26 gross margin slipped 210 bps to 27.4% — the crack that explains the Oct-Jan 30% drawdown and loads the June Q3 print.

Governance grade B− — owner-operator discipline tempered by a controlled-company structure

• Jaffee family controls 69.7% of votes on ~25% of economics. Class B super-voting structure (10 votes per share); CEO Daniel Jaffee (28 years in seat) has never sold a share on the open market across 4 years of Form 4 data.
• Capital allocation is the bright spot. Dividend raised 22 consecutive years (most recently +14% to $0.205/qtr); H1 FY26 buybacks of $19.3M exceed the prior four years combined.
• Pay is restrained, but governance has friction. CEO comp 29:1, no severance/CIC gross-ups — but Vedder Price (director Nemeroff's firm) bills $1.59M/yr and sits on the comp committee.
• Three live red flags. 260,000 Class B shares pledged as personal loan collateral (~$14.7M), two Jaffee-family relatives on payroll (~$700K combined), no disclosed CEO succession plan.

From 1941 garage-floor absorbent to 2026 specialty sorbents — the quiet compounder finally got noticed

1941–2022 — the family compounder. Nick Jaffee borrows $3K from his mother to sell clay granules for garage floors; the business goes public in 1971, builds Cat's Pride into a ~25% US litter share, and runs as a sleepy family-controlled compounder. FY22 was the crisis — natural gas costs per ton +108%, a $5.6M goodwill impairment, net income collapsed 49% to $5.7M. Stock derated as a broken commodity play.

2023–2026 — the rerating. Pricing actions stick, gross margin rebuilds 18% → 25% → 29.5%; Ultra Pet acquisition (May 2024) adds crystal-litter optionality; renewable-diesel filtration drives B2B operating income +31% on +21% revenue in FY25. Stock compounds 228% from the 2022 trough; the 2-for-1 split in Jan 2025 is the flag-plant on a record year.

Stock at an all-time high into a Q3 print where the margin thesis gets tested

• Q2 FY26 was the first crack. Reported Mar 11, 2026 — record sales $117.7M (+1%) but EPS slipped to $0.87 vs $0.89, gross margin compressed 210 bps to 27.4%; management blamed Winter Storm Fern.
• Amlan animal health collapsed 32% YoY. Lost a distributor's key end-customer; B2B operating income fell 18% despite ag (+23%) and co-pack (+31%) strength. The premium-multiple story partly rested on this segment.
• Quant funds piled in while insiders sold. Goldman +123%, Two Sigma +112%, Millennium +75% in Q1-26 13F. Director Hindsley sold $383K two days after the soft Q2 print; last open-market buy by any insider was 34 months ago.

Five material risks — the first two are live and dated

• Gross margin durability. Q2 FY26 at 27.4% is below Quant's 28% line-in-the-sand; two consecutive sub-28% quarters likely triggers 25–30% multiple compression toward 9–10x EBITDA.
• Amlan execution. -32% YoY on one lost customer with no replacement disclosed; the President of Amlan sold $238K of stock three months before the disclosure surfaced.
• Walmart + Clorox concentration. Walmart is 19–20% of consolidated sales; the Fresh Step co-pack makes Clorox simultaneously a major customer and the largest direct shelf competitor.
• Governance overhang. 260,000 pledged Class B shares (~$14.7M margin exposure), Vedder Price related-party fees, two Jaffee relatives on payroll, no succession plan for a 62-year-old controlling CEO.
• Post-rally valuation. 228% rally 2023-2025, within 1% of all-time high, illiquid options — thin float just produced a 30% drawdown on a single soft print.

One gating earnings print decides whether the rerating sticks, all inside six months

• Mid-June 2026 — Q3 FY26 earnings. The single most important data point: gross margin recovery to 29%+ validates the rerating; another sub-28% print derates the stock toward 9–10x EBITDA.
• Mid-June 2026 — Amlan recovery check. Confirmation of whether the lost distributor customer has been replaced; B2B segment OI is the swing factor for FY26 EPS.
• September 2026 — Q4 + full-year FY26. Tests management's soft-reaffirmed promise to surpass FY25 net income of $54.0M despite weather-disrupted H1.
• October 2026 — FY26 10-K and capex update. $32M+ capex run-rate could drag ROIC if B2B expansion outpaces volume; first post-Storm-Fern climate-risk disclosure.
• November 2026 — FY26 proxy. CEO succession framework, status of the Jaffee 260K-share pledge, and Vedder Price fee arrangement all face fresh institutional scrutiny.